ARTICLE | Product Development
Verve impresses investors with second shot at PCSK9
In BioCentury’s Clinical Report, Pfizer and BMS miss out on market opportunities, and more
April 15, 2025 10:10 PM UTC
Despite challenging market conditions, at least one biotech saw its share price rise after reporting clinical data this week.
A second attempt by Verve Therapeutics Inc. (NASDAQ:VERV) to lower LDL cholesterol levels with a base editing therapy is showing promise, with the efficacy of the one-time treatment approaching levels achieved by mAbs against the same PCSK9 target...